Abolis Biotechnologies Funding News – Abolis Biotechnologies Raises €35 Million Financing

Read also - Morphotonics funding news – Netherlands-based Morphotonics Secures $10+ Million in Series B Round Funding

This funding will fuel the company’s expansion into global markets and accelerate its research and development efforts to bring innovative biomanufacturing and microbiome solutions to the market.

Read also - Wingbits funding news – Stockholm-based Wingbits Secures €3.1 Million in Seed Funding

Key players supporting this strategic investment include industry leaders such as BOLD (L'Oréal's venture capital fund), Evonik Venture Capital as well as impact-focused funds including DeepTech & Climate Fonds (Germany), Clay Capital (Singapore), ICOS Capital (Netherlands), and the transatlantic investment firm Liberset.

This funding will enable Abolis to scale its biomanufacturing operations, accelerate business development, develop its own line of products and expand the activities of Microbiome Studio, Abolis’ business unit dedicated to deciphering and engineering microbial ecosystems. The investment is accompanied by the signing of a new strategic industrial partnership between Abolis, L’Oréal and Evonik to bring selected innovations to market, for healthcare, cosmetic and chemical sectors. Beyond the industrial collaboration, this investment will enable Abolis to develop its own portfolio of innovative ingredients, which will be industrialized with partners.

“We are delighted to announce the successful closing of our fundraise with leading industrial partners and industry-focused investors. This strategic funding will fuel our continued growth trajectory, strengthening our position as a European leader in biomanufacturing and microbiome solutions,” declared Cyrille Pauthenier, CEO of Abolis Biotechnologies.

“We are delighted to strengthen L’Oréal’s collaboration with Abolis, which started in 2019, as a long-term partner of the Group at the forefront of sustainable biotechnology,” shared Samantha Etienne, CEO of BOLD, L’Oréal’s venture capital fund. “This investment highlights our belief in Abolis’ potential to create a more sustainable future across various industries, including beauty. We are looking forward to collaborating with the talented Abolis team to support their continued growth and success.”

“Biotechnology as a lever for sustainable transformation is a key component of Evonik's growth strategy,” added Bernhard Mohr, Managing Director Evonik Venture Capital. “Abolis' competencies in strain development and metabolic engineering ideally complement the expertise of Evonik in fermentation processes, downstream processing and scale-up for commercial production. The strategic collaboration of our Business Line Care Solutions with Abolis and L’Oréal alongside our investment will facilitate the access to a wide range of markets, including cosmetics, nutrition and healthcare.”

Since its establishment in 2014, Abolis Biotechnologies previously raised €1.1 million and has since achieved significant growth through strategic partnerships with industry leaders. This new funding round enables Abolis Biotechnologies to enter a new phase of development by expanding its manufacturing platforms dedicated to serving its growing customer base. This expansion will involve the recruitment of talented professionals across all departments, in particular setting up an international Business Development team.

About Abolis Biotechnologies

Abolis Biotechnologies is a French company delivering high-impact innovations in biotechnologies that supports industries in their transition to a more sustainable production model by building a better future in collaboration with Nature. Abolis provides tailor-made industrial solutions based on natural and modified micro-organisms.